We evaluated the baseline demographics, treatment patterns, and outcomes of patients with ALK-rearranged early stage (Stage I-III) non-small cell lung cancer (NSCLC). We also evaluated the efficacy and toxicity of durvalumab consolidation treatment in patients with ALK-rearranged unresectable stage III disease. Treatment strategies and PFS of patients with Stage I-III ALK-rearranged NSCLC are similar to patients without molecular driver alterations. Durvalumab consolidation treatment appears generally safe in patients with unresectable stage III ALK-rearranged disease; however, the degree of benefit of such an approach remains unclear. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2022.01.020
Authors: Sabine Schmid, Miguel Garcia, Sierra Cheng, Luna Zhan, Simren Chotai, Karmugi Balaratnam, Khaleeq Khan, Devalben Patel, M. Catherine Brown, Robin Sachdeva, Wei Xua, Frances A. Shepherd, Adrian Sacher, Natasha B. Leighl, Penelope Bradbury, Patrick Moriarty, M. Sara Kuruvilla and Geoffrey Liu